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Abstract: Bromazepam is a psychoactive drug belonging to class of benzodiazepines with well-known hypnotic and 
sedative effects. It acts on the central neural system as an inhibitor of the neurotransmitter gamma aminobutyric 
acid. It is frequently prescribed for treatment of severe anxiety, to reduce tension, agitation and depression. 
Dissolution testing (the process by which a solid solute enters in to a solution) is a requirement for all solid oral 
dosage forms and is used in all phases of research and development for product release and stability testing. Tablet 
dissolution test is a standardized method for measuring the rate of drug release from a dosage form and it simulates 
the percentage of active substance that can be absorbed into the blood circulation. The direct determination of 
Bromazepam in pharmaceutical dosage forms using HPLC with UV detector to carry out dissolution test, have not 
yet been described. Development of  HPLC method  with UV detection for direct determination of in-vitro 
dissolution test of Bromazepam tablets, which can be used in the same time as method for determination of assay of 
Bromazepam in Bromazepam tablets, can make analytical procedure easier and quicker. A simple, selective, linear, 
precise and accurate RP-HPLC method has been developed and validated for assay and in-vitro dissolution test of 
Bromazepam tablets. The method was validated according to the guidelines set by the International Conference of 
Harmonization for validation of analytical procedures. The chromatographic separation was carried out using 
reversed phase HPLC LiChrospher RP Select B column (125 x 4.0 mm i.d.; 5μm) at temperature of 50oC. Mobile 
phase was consisting of the mixture of methanol, acetonitrile and potassium dihydrogen phosphate buffer (pH 7.0, 
adjusted with 0.5M Potassium hydroxide), with the ratio of 45:5:50 (v/v/v) and flow rate of 1.0 ml/min. The 
detection was carried out at 239 nm. System suitability tests were performed through evaluation of different 
parameters (retention time, tailing factor, retention factor and selectivity) on freshly prepared standard solution of 
bromazepam. The retention time of bromazepam in 0,1M HCl was 3.5 min. High percentage of recovery shows that 
the method is free from the interferences from excipients in test samples. Linearity of response was calculated as a 
ratio of peak areas of bromazepam vs. concentration in 0,1M HCl and spiked tablets in the concentration range of 
0.0018 – 0.016 mgmL-1. The response was linear over the concentration range of 0.0018 – 0.016 mgmL-1 and 
coefficient of correlation was greater than 0.99. Good linearity shows that the proposed method may be useful for 
quickly and routinely determination of the percentage of dissolved bromazepam from bromazepam tablets and it can 
be a method of choice for assay determination in the same time.  
Keywords: Bromazepam; Dissolution; HPLC Determination.    
 
INTRODUCTION   
Bromazepam, chemically described as 7-Bromo-5-(2- pyridyl)-3H-1, 4-benzodiaxepin-2(1H)-one (Figure 1.) is 
white or yellowish crystalline powder, practically insoluble in water and slightly or sparingly soluble in organic 
solutions (ethanol and methylene chloride)
[1]
.  
It is a psychoactive drug belonging to class of benzodiazepines, with well-known hypnotic and sedative effects. It 
acts on the central neural system as an inhibitor of the neurotransmitter gamma aminobutyric acid (GABA)
[2]
. The 
biotransformation is carried out in the liver to 3-hydroxybromazepam through oxidative biotransformation
[3]
. It is 
frequently prescribed for treatment of severe anxiety,  to reduce tension, agitation and depression
[4-5]
. 
According to the literature data, several methods are available for the determination of Bromazepam in 
pharmaceutical dosage forms and biological fluids such as spectrophotometry
[6-8]
, flow injection analysis (FIA) 
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methods
[9]
, differential pulse voltammetry
[10]
 and combination of HPLC-MS
[11]
. Spectroscopy method based on 
second derivative absorption method for the determination of bromazepam in pharmaceutical formulations
[12]
 and 
various HPLC methods were also reported for determination of bromazepam
[13-18]
.  
The direct determination of Bromazepam in pharmaceutical dosage forms using HPLC with UV detector to carry 
out dissolution test, have not yet been described.  
According to Biopharmaceutics Classification System (BCS) of active substances, demonstration of in vivo 
Bioavailability (BA) or Bioequivalence Studies (BE) may not be necessary for drug products containing class 1 and 
class 3 drug substances, as long as the inactive ingredients used in the dosage form do not significantly affect 
absorption of the active ingredients
[19-20]
.   
A systematic study of the development of a BCS-based provisional classification, based on the revised aqueous 
solubility and the apparent permeability across Caco-2 cell monolayers, which displays a high correlation (overall 
76%) with the provisional BCS classification published by World Health Organization (WHO), classifies 
bromazepam in class I
 [21]
.  
Therefore, our objective was to develop a sensitive, reproducible, rapid, and cost-effective RP-HPLC method with 
UV detection for in-vitro dissolution test of Bromazepam tablets, which can be used in the same time as method for 
determination of assay, also. 
 
 
Figure 1. Chemical structure of Bromazepam.    
 
 
EXPERMENTAL PART 
Chemicals and Reagents 
Bromazepam as a Reference Standard was supplied from Merck (B4144 Sigma-Aldrich). Methanol and acetonitrile 
were HPLC grade provided from Sigma Aldrich. All other chemicals were analytical reagent grade. Redistilled 
water was used to prepare solutions for mobile phase. 
Apparatus  
Tablet dissolution test was performed on ERWEKA DT 700, apparatus 2 (paddle).  
Chromatography was performed on Shimadzu Nexera HPLC system equipped with: binary pump, micro vacuum 
degasser, standard autosampler, column compartment and diode array detector (DAD). 
Chromatographic Conditions 
The separation was performed at the temperature of 50
o
C, using an isocratic method and reversed-phase HPLC 
LiChrospher RP Select B column (125 x 4.0 mm i. d.; particle size 5 μm) from Merck KGaA (Darmstadt, Germany). 
The choice of solvent for the preparation of standard and test solustions was made considering the solubility of 
bromazepam.  
 The mobile phase containing a mixture of methanol, acetonitrile and potassium dihydrogen phosphate (KH2PO4) 
buffer (pH 7.0, adjusted with 0.5M Potassium hydroxide), in the ratio 45:5:50 % v/v/v and flow rate of 1.0 ml min
-1
 
gave the best separation of the peak of bromazepam without interference with other components from the 
pharmaceutical formulation.  
The detection was carried out at 239 nm. 
The injection volume of samples was 20 µl.    
Chromatographic data were analyzed using Shimadzu software following the requirements for chromatographic 
analysis. Regression calculations were done with Microsoft Excel. 
Preparation of KH2PO4 buffer  
11,33 g of KH₂PO₄ were weighted and transferred into 1000- ml flask, and then water was added to the mark. pH 
was adjusted to 7.0 with 0.5M Potassium hydroxide. 
Standard Solutions and Calibration Curves 
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The standard stock solution of bromazepam was prepared by dissolving of Bromazepam in methanol 
(conc.0,5mg/ml) and diluting with 0,1M hydrochloric acid (HCl) to achieve the concentration of bromazepam in the 
range of 0.0018–0.016 mg mL-1. The calibration curve was constructed by plotting the ratio of the peak area of the 
drug against the drug concentration. All solvents and solutions for HPLC analysis were filtered using a membrane 
filter (0.45 μm pore size) and were vacuum degassed before use.   
Validation of the Method 
The proposed method was validated according to the guidelines set by the International Conference of 
Harmonization for validation of analytical procedures [22,23].  The precision and reproducibility of the proposed 
method were evaluated by performing replicate analysis of the standard solution to determine intra-day and inter-day 
variability (within day (n = 5) and between days (n = 5) for three different concentrations. Relative standard 
deviations were calculated to obtain the precision of the method.  The stock solution of Bromazepam was prepared 
by dissolving 25mg of Bromazepam reference standard in methanol and diluted with methanol up to 25 ml. Working 
standard solutions were prepared by appropriate dilution with 0,1M HCl to achieve final concentrations of 
bromazepam (0.0018 mgmL
-1
, 0.0084 mgmL
-1 
and 0.016 mgmL
-1
). 
Recovery Studies 
To establish the accuracy and reliability of the proposed method, recovery experiments were carried out by adding 
the known quantities of bromazepam in placebo. Tablets were previously dissolved in methanol and then diluted 
with 0.1M HCl. Calculations were made after five repeated injections.  The amount of bromazepam in spiked 
placebo samples was calculated from the linear regression equation.   
Limit of Detection and Limit of Quantification 
The limit of detection (LOD) and limit of quantitation (LOQ) were calculated using following formula: LOD = 3.3 
SD/S and LOQ = 10 SD/S, where SD is the standard deviation of the response (peak area) and S is the slope of the 
calibration curve obtained.   
Experimental in-vitro dissolution test  
In-vitro dissolution test was performed on 6 tablets on ERWEKA DT 700 apparatus. As dissolution medium 500ml 
of 0,1M HCl was used. After the equilibration to 37°C ± 0.5°C, each tablet was place in the dissolution medium and 
apparatus was immediately switched on 75 rpm for 45 minutes.  Samples before injection into HPLC column were 
filtered through a 0.45 µm filter. 
 
RESULTS AND DISCUSSION   
Tablet dissolution test is a standardized method for measuring the rate of drug release from a dosage form
[24]
.  
Initial experiments were carried out using the mobile phase consisting of KH2PO4 buffer, methanol and acetonitrile 
in different proportions and at different pH values. Mobile phase composition of mixture of methanol, acetonitrile 
and potassium KH2PO4 buffer (pH 7.0, adjusted with 0.5M Potassium hydroxide) was found to be optimal for good 
peak resolution for bromazepam. The optimum wavelength for detection was 239 nm.   
System suitability tests were performed through evaluation of different parameters (retention time, tailing factor, 
retention factor and selectivity) on freshly prepared standard solution of bromazepam (conc. 0.0084 mgmL
-1
).  The 
retention time of bromazepam in 0,1M HCl was 3.5 min. Tailing and retention factors for bromazepam were 
obtained as 1.08 and 1.13. The variation in retention time of bromazepam among five replicate injections of standard 
solution in 0,1M HCl was very slight, giving the relative standard deviations (RSD %) of 0.25% calculated on peak 
area and 0.33% calculated on retention time.    
The calibration characteristics and validation parameters of the proposed method are shown In Table 1. Linearity of 
response was calculated as a ratio of peak areas of bromazepam vs. concentration in 0,1M HCl and spiked tablets in 
the concentration range of 0.0018 – 0.016 mgmL-1. Coefficient of correlation was greater than 0.99 for both.  The 
Figure 2 shows a calibration curves from bromazepam standard solution (a) and bromazepam in spiked placebo 
tablets (b).   
Table 1. Characteristics of the linear regression analysis 
 0,1M HCl Spiked tablets 
Linearity range (mgmL
-1
) 0.0018–0.016 0.0018 -0.016 
Slope 1E + 08x 1E + 08 
Intercept 20744 39403 
Determination coefficient (r
2
) 0.9998 0.9995 
Detection limit (mgmL
-1
)                            0.0075 0.0088 
Quantification limit (mgmL
-1
)                     0.0172 0.0232 
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Figure 2. Calibration curves from bromazepam standard solution (a) and bromazepam in spiked placebo tablets (b).   
The results of precision, accuracy (recovery), and reproducibility (assay) of the method are shown in Table 2. They 
demonstrate a good precision (determined as the RSD %), accuracy, and reproducibility.  
Table 2. Precision and accuracy of the method 
Concentration 
added  
(mg mL-1) 
 
Measured concentration (mg mL-1)a 
 
 In 0,1M HCl 
 Intra-day  Inter-day  
   
 Mean (mg mL-1) 
± RSD (%) 
Mean (mg mL-1) 
± RSD (%) 
0.0018 0.0525 ± 0.75 0.0584 ± 1.13 
0.0084 0.2722 ± 0.88 0.2713 ± 0.72 
0.016 0.3431 ± 1.13 0.3447 ± 1.45 
               a
 Mean value of five determinations 
The Figure 3-a shows a typical chromatogram of the placebo.  The Figure 3-b shows chromatogram of 0,1M HCl 
used as solvent, the Figure 3-c shows chromatogram of bromazepam standard solution in 0,1M HCl, while the 
Figure 3-d shows chromatogram of test solution. There are no any extraneous peaks from excipients in 
chromatograms obtained in test samples.     
All obtained results can confirm that the proposed method can be applied for in-vitro dissolution testing of 
bromazepam tablets.  In the Table 2 we present the results obtained by HPLC analysis of the spiked samples with 
bromazepam.  
  
  
Figure 3. Chromatograms of placebo (a), 0,1M HCl used as solvent (b), bromazepam in 0,1M HCl (c) and test 
solution (d) 
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CONCLUSION   
The aim of this paper was to develop HPLC method with UV detection which can be used in the same time for 
determination of assay and in-vitro dissolution of bromazepam tablets, bearing in maid that direct determination of 
Bromazepam in pharmaceutical dosage forms using HPLC with UV detector to carry out dissolution test, have not 
yet been described.  
The proposed RP-HPLC method is a simple, accurate, precise and rapid for determination of assay and in-vitro 
Dissolution test of Bromazepam tablets. The developed HPLC method was fully validated by evaluation of the 
validation parameters. High percentage of recovery shows that the method is free from the interferences from 
excipients in test samples. Good linearity shows that the proposed method may be useful to determine the 
percentage of dissolved bromazepam from bromazepam tablets and it can be a method of choice for assay 
determination in the same time.  
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